Cutaneous Mycosis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Cutaneous Mycosis – Drugs In Development, 2024 report and make more profitable business decisions.
Cutaneous mycoses are a group of superficial fungal infections that affect the skin, hair, and nails. They are also known as superficial mycoses. They are confined to the outer layers of the skin, hair, or nails. They rarely invade deeper tissues or viscera, and do not induce a cellular response from the host. Most cutaneous mycoses are caused by dermatophytes, a group of filamentous fungi that colonize and infect keratinized tissues, including the outermost layer of skin.
The Cutaneous Mycosis drugs in development market research report provide comprehensive information on the therapeutics under development for Cutaneous Mycosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cutaneous Mycosis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Cutaneous Mycosis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 17 molecules, with 16 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Cutaneous Mycosis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Cutaneous Mycosis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Cutaneous Mycosis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Almirall SAAmtixbio Co Ltd
ASCIL Biopharm
Blueberry Therapeutics Ltd
China Medical System Holdings Ltd
CSA Biotechnologies LLC
Hallux Inc
Moberg Pharma AB
Mycovia Pharmaceuticals Inc
NAL Pharmaceuticals Ltd
Nektr Technologies Ltd
Photonamic GmbH & Co KG
SaNOtize Research and Development Corp
Tianjin Institute of Pharmaceutical Research
TIPR-HUYA Advancing Innovative Medicines
TTY Biopharm Co Ltd
Turn Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Cutaneous Mycosis reports